Management of dyslipidemia in adults with diabetes

Diabetes Care

Volumn 26, Issue SUPPL. 1, 2003, Pages

  Haffner, Steven M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; DIET THERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037678289     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2007.s83     Document Type: Review

References (12)

1. Haffner SM: Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 21:160-178, 1998
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ 316:823-828, 1998
4. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
5. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 26 (Suppl. 1):S51-S61, 2003
6. American Diabetes Association: Diabetes mellitus and exercise (Position Statement). Diabetes Care 24:S51-S55, 2001
7. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC, Washington R: When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association task force on risk reduction. Circulation 95:1683-1685, 1997
8. Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of the National Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (Suppl.):525-584, 1992
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
10. American Diabetes Association: Detection and management of lipid disorders in diabetes (Consensus Statement). Diabetes Care 16:828-834, 1993
11. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
12. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pederson TR, Kjekshus J, Pyorala K: Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 22:1771-1778, 1999